Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06511570 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
A Phase 1 study, sponsored by Acumen Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT06511570 is a Phase 1 study that has completed, run by Acumen Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT06511570, a Phase 1 study, has completed, sponsored by Acumen Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
Interventions
- DRUG sabirnetug (ACU193)
- COMBINATION_PRODUCT Sabirnetug + rHuPH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2024-09-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06511570
The ClinicalTrials.gov registry entry for NCT06511570 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acumen Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sabirnetug (ACU193) is the first listed.
NCT06511570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06511570 about?
NCT06511570 is a clinical study titled "A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants". A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
What is the current status of trial NCT06511570?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2024-06-25. Estimated completion is 2024-09-17.
What interventions are being tested in trial NCT06511570?
The interventions under investigation include: sabirnetug (ACU193) (DRUG), Sabirnetug + rHuPH20 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06511570?
This trial is sponsored by Acumen Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.